linjc16/ctgov huggingface dataset:
Growth and Adiposity in Newborns: The Influence of Prenatal Docosahexaenoic Acid (DHA) Supplementation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to learn if participants in the ADORE study (NCT02626299), who took a DHA supplement during pregnancy, see favorable body fat in their infants from birth to 24 months, and if excessive or appropriate weight gain during pregnancy impacts this result.

Official Title
-----------------
Growth and Adiposity in Newborns: The Influence of Prenatal Docosahexaenoic Acid (DHA) Supplementation

Conditions
-----------------
Pregnancy; Nutritional Diseases

Intervention / Treatment
-----------------
* Dietary Supplement: Docosahexaenoic acid


Participation Criteria
=================
Eligibility Criteria
-----------------
Participants for this study are invited from the parent study, ADORE. Eligibility listed reflects criteria for the ADORE study. Inclusion Criteria: Agree to consume study capsules and a typical prenatal supplement of 200 mg DHA Available by telephone Exclusion Criteria: Expecting multiple infants Gestational age at baseline <12 weeks or >20 weeks Unable or unwilling to agree to consume capsules until delivery Unwilling to discontinue use of another prenatal supplement with DHA that contains ≥ 200 mg DHA Women with allergy to any component of DHA product (including algae), soybean oil or corn oil

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ADORE Participants<br>Participants enrolled in the ADORE study are invited to participate in this study. | Dietary Supplement: Docosahexaenoic acid<br>* The main study, ADORE, includes providing DHA to participants during pregnancy. No intervention is included as part of this study.<br>* Other names: DHA;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Infant Fat Mass (FM) | Difference in FM in offspring exposed to high vs. low DHA and excessive vs. non-excessive GWG | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Central Fat Mass | Difference in FM in offspring exposed to high vs. low DHA and excessive vs. non-excessive GWG | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fat mass, Gestational weight gain, Fetal adipose tissue
Musculoskeletal Complaints in an Industry

Study Overview
=================
Brief Summary
-----------------
The hypothesis of this study is that there will be a variety of factors influencing the musculoskeletal complaints among workers of different sectors. Work-related musculoskeletal disorders (WMSDs) account for more than 30% of occupational diseases in the world. In order to organize the strategic actions that will be developed for the prevention of MSDs, it is essential to analyze in advance the peculiar situations of the different sectors of a workplace. The objectives of this study were to determine the prevalence of musculoskeletal complaints among workers in a medium-sized industry by comparing its sectors and to investigate the influence of occupational and non-occupational factors in the increase of complaints.

Detailed Description
-----------------
The Nordic questionnaire was used to asses musculoskeletal symptoms as well as questionnaires about lifestyle and work-related conditions in 185 workers divided into three sectors of an industry (factory - microelectronics, office and logistics)

Official Title
-----------------
Factors That Influence the Prevalence of Musculoskeletal Complaints Among Workers in Different Sectors of an Industry

Conditions
-----------------
Musculoskeletal Disorder

Intervention / Treatment
-----------------
* Other: questionnaires


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: work in the industry Exclusion Criteria: work less than a month in the industry
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Muskind<br>three questionnaires to be completed by the subjects | Other: questionnaires<br>* 185 industry workers divided in three sectors (factory, office and logistics) were assessed using the Nordic Musculoskeletal Questionnaire and lifestyle and work-related conditions questionnaires.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| musculoskeletal complaints | musculoskeletal complaints in different parts of the body | one month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
work, WMSD, prevalence, occupational risks, industry, questionnaires, musculoskeletal pain, lifestyle
Effect of a Probiotic, Lactobacillus FARCIMINIS, in Diarrhea Predominant IBS Patients

Study Overview
=================
Brief Summary
-----------------
Probiotics may improve symptoms in IBS patients. The aim of this study is to test the efficacy of Lactobacillus FARCIMINIS in diarrhea predominant IBS patients according to Rome III criteria.

Detailed Description
-----------------
The aim of this study is to test the efficacy of Lactobacillus FARCIMINIS in diarrhea predominant IBS patients according to Rome III criteria.

Official Title
-----------------
Effect of a Probiotic, Lactobacillus FARCIMINIS, in Diarrhea Predominant IBS

Conditions
-----------------
Irritable Bowel Syndrome

Intervention / Treatment
-----------------
* Dietary Supplement: Lactobacillus FARCIMINIS
* Dietary Supplement: placebo (starch)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diarrhea predominant IBS Less than 5-year duration Pain intensity between 2 and 7 on VAS Exclusion Criteria: Celiac disease Antibiotic treatment within the 1-month period preceding inclusion Digestive organic disease Any severe non digestive organic disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br>Lactobacillus FARCIMINIS | Dietary Supplement: Lactobacillus FARCIMINIS<br>* 10.10 UFC of lactobacillus FARCIMINIS<br>* Other names: 10.10 UFC of lactobacillus FARCIMINIS;|
| Placebo Comparator: B<br>Placebo | Dietary Supplement: placebo (starch)<br>* Once daily<br>* Other names: Once daily;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall subject's assessment |  | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Decrease in abdominal pain, stool form and consistency, modifications in intestinal permeability, modification in fecal serine protease activity, modifications in interleukin seric concentrations |  | 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IBS, Diarrhea, Rome III
A Single Center Registry of Coronary OCT

Study Overview
=================
Brief Summary
-----------------
This registry started January 1,2020 to collect patients who recieve coronary OCT imaging in Hainan General Hospital.All enrolled patients will receive 1 year followed-up.

Detailed Description
-----------------
This registry started January 1,2020.Patients >= 18 years old who recieve coronary OCT imaging in Hainan General Hospital are included in current registry.

Official Title
-----------------
A Registry of Coronary Artery Optical Coherence Tomography of Hainan General Hospital

Conditions
-----------------
Coronary Artery Disease, Optical Coherence Tomography, Registry

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects who recieved intracoronary OCT imaging during cardiac catheterization are eligible for this registry. Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major adverse cardiac events (MACE) |  | 1 years |
Study of Subthalamic Brain Stimulation in Parkinson Disease (PD)

Study Overview
=================
Brief Summary
-----------------
Deep brain stimulation (DBS) improves debilitating symptoms of movement disorders when conventional medical therapies and novel surgical therapies fail. Despite the remarkable efficacy of DBS, its therapeutic mechanism remains unclear. There is controversy regarding whether the therapeutic effects of DBS are associated with inhibition or excitation of target neurons, the introduction of new activity into the network, or a combination of these mechanisms. Additionally, it is unclear why stimulus frequency plays an important role in the clinical response to therapy. The fundamental hypothesis of this proposal is that unilateral subthalamic nucleus (STN) DBS in PD alters neuronal activity in the bilateral basal ganglia-thalamic-cortical motor system in a manner that is dependent on stimulation frequency.

Official Title
-----------------
Clinical and Neurophysiological Study of Subthalamic Brain Stimulation in PD

Conditions
-----------------
Parkinson Disease

Intervention / Treatment
-----------------
* Device: Implantable pulse generator (deep brain stimulator)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Parkinson disease who have undergone subthalamic deep brain stimulation Exclusion Criteria: Patients who are unable to follow verbal instructions Patients who are unable to tolerate being off their Parkinson's medications for 12 hours Patients who are medically unstable

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Implantable pulse generator (deep brain stimulator)|This study evaluates the effects of subthalamic deep brain stimulation on central and peripheral nervous system activity in patients who have already had brain stimulators placed as a matter of routine clinical care.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| This study measures neurophysiological responses to subthalamic deep brain stimulation in the central and peripheral nervous system in patients with Parkinson disease. |  | Population data will be analyzed for the primary endpoint in 12 months and reported in approximately 18 months. |
Epidemiological Study on Mental Health of Migrant Population in the Retention Center of Geispolsheim.

Study Overview
=================
Brief Summary
-----------------
In 2019, the lack of studies about mental health of the detained population at retention centers in France is pointed out by the report of Controller-General for Places of Deprivation of Liberty. The aim of this study is to contribute to this relatively untouched field by describing which psychiatric pathologies are encountered in this population who went through migration and retention. Having a clearer picture of the situation can help to provide a more adapted psychiatric care in retention centers. The results are expected to show a higher rate of psychiatric disease than in the general population including addiction to substance, anxiety disorder and post-traumatic stress disorder (PTSD).

Official Title
-----------------
Epidemiological Study on Mental Health of Migrant Population in the Retention Center of Geispolsheim

Conditions
-----------------
Mental Health of Migrant Population

Intervention / Treatment
-----------------
* Behavioral: Retention center Geispolsheim population


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any male person in the first week of detention at CRA Geispolsheim who gave their non-opposition to participation in the study. Information and consent protocol signed Exclusion Criteria: Refuse to participate to the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Retention center Geispolsheim population|All recently held individuals in the retention center can be included in the study after signing the information and consent protocol.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mini International Neuropsychiatric Interview validated and translated in the language used by the interviewed person. | The interview is led by the investigator in the presence of a translator if necessary. | 1 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Mental health, Psychiatric diseases, Migration, Retention center
Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the long-term safety and efficacy of imidafenacin.

Official Title
-----------------
An Open-label Study to Evaluate the Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder

Conditions
-----------------
Overactive Bladder

Intervention / Treatment
-----------------
* Drug: imidafenacin, KRP-197/ONO-8025
* Drug: imidafenacin, KRP-197/ONO-8025


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men and Woman equal or > 20 years old Patients with urgency, urinary frequency and urgency incontinence Exclusion Criteria: Patients with genuine stress incontinence Patients suffering from complications such as bladder tumor, urinary tract stone and symptomatic urinary tract infection Patients suffering from complications contraindicating the use of antimuscarinic medication Patients with polyuria

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: E1<br> | Drug: imidafenacin, KRP-197/ONO-8025<br>* 0.1 mg BID for 52 weeks<br>|
| Experimental: E2<br> | Drug: imidafenacin, KRP-197/ONO-8025<br>* 0.1 mg BID for 12 weeks and 0.2 mg BID for 52 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety Measures: adverse events, laboratory tests, 12-lead ECG, vital signs, post-void residual volume |  | 64 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy measures: number of urgency incontinence episodes per week, number of incontinence episodes per week, number of micturitions per day, number of urgency episodes per day, severity of urgency, urine volume voided per micturition, Quality of Life |  | 64 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Imidafenacin, KRP-197/ONO-8025, overactive bladder, antimuscarinic
The Genetics Behind Vitamin D Status (VitDgen)

Study Overview
=================
Brief Summary
-----------------
The overall purpose of the study is to investigate whether there is a relationship between 26 different single nucleotide polymorphisms (SNPs) in the vitamin D pathway, ultraviolet B (UV-B) irradiation of the skin and vitamin D status. The hypothesis is that vitamin D status are influated by different genetic genotypes in the vitamin D pathway.

Detailed Description
-----------------
In this study approximately 80 participants (over 18 years) are included. All the participants has previously participated in the VitmaD intervention study (NCT01184716) . Participants will in total receive 4 times UV-B irradiation (3 SED) with two day apart each time, to stimulate vitamin D production in the skin. The participants skintype will be measured. The study starts in January 2013 and runs to the end of Marts 2013. During this winter period, it is in Denmark not possible to produce vitamin D in the skin through sunlight exposure.

Official Title
-----------------
The Genetics Behind Vitamin D Status (VitDgen)

Conditions
-----------------
Vitamin D Deficiency

Intervention / Treatment
-----------------
* Genetic: VitDgen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Health participants over 18 years, that previously participated in VitmaD intervention study Exclusion Criteria: skindiseases intake of medicin that causes photosensitive skin pregnant or nursing sun vacation 3 month before the intervention intake of vitamin D supplement 3 month before the intervention

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: UV-B irraditation<br>VitDgen | Genetic: VitDgen<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum 25-hydroxyvitamin D | Measures the vitamin D status i serum at baseline and at the end of the project | 10 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Skintest | Optimize scientific; measures pigmentation and redness of the skin. Are measured at baseline and at end of project | 10 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
vitamin D, SNPs, Vitamin D status, UVB irradiation, genetics
Identification of Anaphylactogenic Antibodies in Peanut Allergy

Study Overview
=================
Brief Summary
-----------------
This project intends the analysis and profiling of specific antibodies against major peanut allergens in peanut allergic individuals and molecular cloning of human antibodies against major peanut allergens.

Detailed Description
-----------------
Characterization of patient samples reactivity (sera obtained from blood) against major peanut allergens. Isolation of antibody-producing B cells. Molecular cloning of peanut-specific antibodies from antibody gene sequences obtained from B cells. Biophysical and functional characterization of isolated antibodies

Official Title
-----------------
Identification of Anaphylactogenic Antibodies in the Blood of Peanut Allergic Patients

Conditions
-----------------
Peanut Allergy

Intervention / Treatment
-----------------
* Other: Observational study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants have a described clinical history of peanut allergy and/or are sensitized to peanut allergens (as evidenced by positive skin prick test and allergen-specific IgE testing) Male and female subjects older than 3 years Written informed consent Exclusion Criteria: age below three years patients suffering from any disease where blood withdrawals might impact the patients' health status such as known anemia.

Ages Eligible for Study
-----------------
Minimum Age: 3 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Observational study|Blood sampling|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analysis and profiling of specific antibodies against major peanut allergens in samples derived from peanut allergic patients. |  | June 2016 to May 2018 |